IL-2 Superkine-Recombinant Human Albumin Fusion Protein MDNA11

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A long-acting formulation consisting of an engineered and mutated form of the endogenous cytokine interleukin-2 (IL-2; IL2) fused with human recombinant albumin, with minimal to no binding affinity for IL-2 receptor subunit alpha (IL-2Ralpha; CD25) and with high binding affinity for the beta receptor subunit (IL-2Rbeta; IL2Rb; CD122), with potential immunostimulating and antineoplastic activities. Upon administration, IL-2 superkine-recombinant human albumin fusion protein MDNA11 primarily targets and preferentially binds to CD122. The binding of IL-2 to CD122 activates IL2Rb-mediated signaling in immune cells, which activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell- and NK-mediated cytotoxic immune responses against tumor cells causes tumor cell destruction. The fusion of IL-2 with human recombinant albumin allows for longer half-life and enables accumulation at the tumor site.. As MDNA11 does not bind to CD25 expressed on regulatory T-cells (Tregs), the IL-2-mediated activation of Tregs and Treg-mediated immunosuppression is halted.

**Synonyms:** - Long-acting IL-2 Fusion Protein MDNA11 - MDNA 11 - MDNA-11 - MDNA11 - Superkine IL-2 MDNA11